March 2018, Vol 11, Ninth Annual Payers' Guide

FDA Approvals, Payers' Guide

Welcome to the Ninth Annual Payers’ Guide to New FDA Approvals

FDA Approvals, Payers' Guide

FDA Approvals in 2017 Represent a 21-Year High

Gary M. Owens, MD

FDA Approvals, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2017

Select Drug Profiles, Payers' Guide

Aliqopa (Copanlisib), an Intravenous PI3K Inhibitor, Approved for Patients with Relapsed Follicular Lymphoma

Lisa A. Raedler, PhD, RPh

Lung Cancer, Select Drug Profiles, Payers' Guide

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Bavencio (Avelumab) Approved for Metastatic Merkel-Cell Carcinoma and for Urothelial Carcinoma

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Select Drug Profiles, Payers' Guide

Dupixent (Dupilumab) First Biologic Drug Approved for Patients with Moderate-to-Severe Atopic Dermatitis

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Dysport (AbobotulinumtoxinA) Now FDA Approved for the Treatment of Lower-Limb Spasticity in Adults

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Gazyva (Obinutuzumab) Approved as First-Line Treatment, with Chemotherapy, for Patients with Follicular Lymphoma

Lisa A. Raedler, PhD, RPh

1
2
3
4

Page 1 of 4
Results 1 - 10 of 31

SUBSCRIBE

Copyright © Amplity Medical Communications. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.